Joint contractures; ankylosing spondylitis; Dupuytren’s contracture (initial stage); scarring of the skin of various origins; hematomas (in the organization stage); scleroderma; in ophthalmological practice (keratitis, retinopathy); productive character of lung inflammation in patients with pulmonary tuberculosis; traumatic lesions of the nerve plexus and peripheral nerves; rheumatoid arthritis.
active substance: 1 ampoule or vial contains 64 UNITS of hyaluronidase (obtained from the testes of cattle);
Lidaza-Biofarma Dosage form
Powder for solution for injection.
Main physical and chemical properties: the powder is compacted into a tablet or lyophilized porous mass from white to cream color of different intensity. The presence of dry crust is allowed on the surface.
Lidaza-Biofarma Pharmacotherapeutic group
Hematological agents. Enzymes. ATX code B06A A03.
Hyaluronidase is an enzyme whose specific substrate is hyaluronic acid. The latter is a mucopolysaccharide, which consists of acetylglucosamine and glucuronic acid. Hyaluronic acid has a high viscosity; biological significance – “cementing” intermediate substance of connective tissue. The effect of the drug is to improve joint mobility, soften scars, eliminate and reduce contractures, resorption of hematomas. The effect is most pronounced at the initial stage of pathological processes. Hyaluronidase (“spread factor”) causes the breakdown of hyaluronic acid to glucosamine and glucuronic acid, and thus leads to increased tissue permeability and improved movement of interstitial fluids. The effect of hyaluronidase is reversed – reducing the concentration restores the viscosity of hyaluronic acid.
Dupuytren’s contracture (initial stage);
scarring of the skin of various origins;
hematomas (at the stage of organization);
in ophthalmic practice (keratitis, retinopathy);
productive nature of pneumonia in patients with pulmonary tuberculosis;
traumatic lesions of the nerve plexuses and peripheral nerves;
Hypersensitivity to the active substance;
acute infectious-inflammatory processes;
pulmonary hemorrhage and hemoptysis;
use of estrogen;
acute stage of hematoma;
tuberculosis with severe pulmonary insufficiency.
Interaction with other medicinal products and other forms of interaction
The drug accelerates the absorption of other drugs (local anesthetics, isotonic solutions, muscle relaxants) by subcutaneous and intramuscular administration of the latter.
Features of application
The drug can be used in conjunction with physiotherapy treatments, including phonophoresis.